MONTEFIORE MEDICAL CENTER

Size: px
Start display at page:

Download "MONTEFIORE MEDICAL CENTER"

Transcription

1 DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September 2006, June 2009, May 2012, May 2015, July 2015, August 2015, May 2016, November 2016, January 2017 APPROVED BY: Unified Director of Pharmacy REVIEWED BY/DATE: The Pharmacy and Therapeutics Committee, in approving the addition of certain antibiotics to the Formulary, may restrict their use because of toxicity, and in an attempt to minimize antibiotic resistance. Monitoring of the usage of these antibiotics is the responsibility of the Antibiotic Subcommittee, the Division of Infectious Diseases, the Antibiotic Stewardship Program and the Pharmacy Department. 1. Prescribers wishing to prescribe any restricted antibiotics during designated hours of restriction (see Table 1 for hours of restriction according to division) should contact the designated person [a member of Infectious Diseases (ID) or Antimicrobial Stewardship Program (ASP)] on call for antibiotic approval. Table 1. Hours of Restriction by Division Division / Patient Population Days of Restriction Hours of Restriction Moses and Einstein 7 days per week 8 AM to 11PM Wakefield Weekdays* (excluding official holidays) 9:30 AM to 5 PM Pediatric and NICU Patients 7 days per week 8 AM to 11 PM *ID consultation must still be obtained for drugs requiring mandatory consult within 24 hours The prescribers and member of ID/ASP will discuss the appropriateness of the request. If clinically indicated, member of ID/ASP will either place approval note under stewardship ABX approval note in Epic or call the pharmacy and provide the following information: a. Name of patient b. Medical record number c. Location of patient d. Drug name, dosage, route, administration frequency, and duration of approval e. Name of antibiotic approver 1

2 If the restricted antibiotic has not been approved by a member of ID/ASP, pharmacists must call the prescribers to inform them that the antibiotic requires ID approval and enter as intervention (Ivent) in Epic. In instances when prescribers are unable to reach ID/ASP within one hour, prescribers must call the pharmacy and ask for two doses to be dispensed to allow for additional time to obtain approval. A list of these incidents will be generated the following morning by pharmacy for follow up by a member of ID/ASP. Pharmacists should not automatically dispense the two doses of antibiotic, but should wait for the return call from prescribers indicating they were unable to reach ID/ASP. If prescribers do not call back requesting the release of the two doses, no antibiotic should be dispensed. If ID/ASP does not call the pharmacy to release the restricted antibiotics, no further medication will be dispensed. 2. A limited number of doses (i.e. sufficient to maintain patient until stewardship hours resume) of designated, restricted antibiotics (Table 3, Category III Antibiotics at Moses and Einstein Divisions) can be dispensed without approval from ID/ASP if requested during non-stewardship hours (see table 2). Pharmacists should remind prescribers that approval must be obtained (as outlined in Section 1) for continuation of therapy. Table 2. Hours During Which Limited Doses May Be Dispensed Division / Patient Population Day Time Moses and Einstein 7 days per week 11PM 8AM Wakefield Monday Friday Weekends Holidays 5:00PM 9:30 AM All hours All hours CHAM 7 days per week 11PM 8AM 3. Upon receipt of an order for a restricted antibiotic, pharmacists should verify the order only if ID approval has been obtained as per ABX approval note in Epic. If ID approval is pending, the medication order should not be verified, and pharmacists should follow the procedure outlined in Section 1 above. Once ID approval is obtained, the medication order should be verified by pharmacists, and the appropriate number of doses sent to the patient unit. Pharmacists should modify the antibiotic orders to match the dose, route, frequency, and duration of approval. 4. The following adjustments in restricted antibiotic therapy are regarded as new orders and will require new approval as described in Section 1: a. Increased dose of the drug b. Increased frequency of administration c. Increased (extended) duration d. Changing from the oral to the parenteral route of administration. 2

3 5. The Director for Clinical and Educational Pharmacy Services will ensure that restricted antibiotics are approved by the responsible departments through scheduled Pharmacy Performance Improvement Initiatives. 5.1 It is the responsibility of pharmacists on duty to ensure each restricted antibiotic is approved by ID or ASP in a timely fashion. 5.2 The lists of Restricted Antibiotics (Tables 3-6) are updated as necessary. They are distributed to Department of Pharmacy staff, Division of Infectious Diseases and posted on pharmacy and Infectious Diseases intranet sites Reviewed by: Yi Guo, PharmD Nidhi Saraiya, PharmD Philip Lee, PharmD Belinda Ostrowsky, MD Priya Nori, MD Vijaya Soma, MD 3

4 Table 3. Restricted Antimicrobial List for Moses and Einstein (Adults) as of March 2017 Category I - I.D. approval and consultation must be requested when given to adults. These generally should not be started during the overnight hours. Ampho B deoxycholate Ampho B lipid formulations Artemether/lumefantrine PO Ceftaroline Ceftazidime/avibactam Ceftolozane/tazobactam Chloramphenicol (The oral formulation is no longer made in the U.S.) Cidofovir Daptomycin Fidaxomicin PO Flucytosine PO Foscarnet Fosfomycin PO IG Need ID approval/consult for any infectious diseases indications (i.e. C. difficile colitis, group A streptococcal or MRSA toxic shock syndrome). Linezolid, PO (Patients are automatically switched to the oral formulation when able to take oral medications) Meropenem Micafungin ID consultation/approval is not required for 50 mg daily doses in allogeneic stem cell recipients who require antifungal prophylaxis. Pentamidine Polymyxin B Pyrimethamine PO Ribavirin Inhalation Tigecycline Voriconazole, PO Category II - I.D. approval must be requested when given to adults. A consultation is suggested, but not required. Oseltamivir Oral Category III - I.D. approval must be requested from 8 A.M. to 11 P.M., but one or two doses may be dispensed from 11 P.M. to 8 A.M. without approval when being given to adults. Acyclovir Approval is not required for 250 mg q12h prophylaxis doses in stem cell recipients unable to take oral valacyclovir. Albendazole PO Amikacin, IM Azithromycin Approval not required for 1 st dose ordered via Severe Sepsis Protocol Aztreonam Approval not required for 1 st dose ordered via Severe Sepsis Protocol Cefepime Approval is exempt for oncology patients in NW 2 (Moses) and 11S (Einstein) and patients in critical care units (not step-down patients). Approval is not required for 1 st dose ordered via Severe Sepsis Protocol. Cefotaxime For Pediatrics only (ceftriaxone should be used for adults) Ceftriaxone Approval is not required for doses up to 1000 mg per day. 1 st dose of > 1 gm is exempt from approval if ordered via Severe Sepsis Protocol. Ciprofloxacin Approval is not required for peri-operative LVAD surgery prophylaxis for up to 48 hours, for prophylaxis doses in stem cell recipients, or for 1 st dose ordered via Severe Sepsis Protocol. Patients are automatically switched to the oral formulation when able to take oral medications. Clarithromycin PO Approval is not required for the treatment of Mycobacterium avium and H. pylori infections. Fluconazole, PO Approval is not required for H patients, for prophylaxis in stem cell recipients receiving up to 400 mg/day, for peri-operative LVAD surgery up to 200mg/day x 48 hours, and for single 150mg PO dose for candidal vaginitis. Patients are automatically switched to the oral formulation when able to take oral medications. Ganciclovir Itraconazole PO Ivermectin PO Levofloxacin, PO Approval is not required for oral doses 500 mg daily. Patients are automatically switched to the oral formulation when able to take oral medications. Penicillin G benzathine (Bicillin LA) IM Piperacillin/tazobactam Approval is required only for patients in the Emergency Room and on Vascular Surgery, however 1 st dose ordered via Severe Sepsis Protocol is exempt from approval. Posaconazole PO (Please note suspension and extended-release tablet dosing is NOT interchangeable) Tobramycin Inhalation Vancomycin, PO, and Approval is not required for the initial 72 hours of the therapy. Approval is not required for therapy for rectal per-operative LVAD surgery prophylaxis x 48 hours. 4

5 Table 4. Restricted Antimicrobial List for Wakefield Inpatients as of March 2017 Category I - I.D. stewardship approval and ID consultation must be requested within 24 hours. From 5:01 p.m. 9:29 a.m. on M-F, on weekends, or holidays, pharmacy will authorize a sufficient duration of therapy until an ID consult can be obtained (24 hours) Non-formulary antimicrobials require ID consultation and approval prior to dispensing. Ampho B deoxycholate Ampho B lipid formulations Artemether/lumefantrine PO Ceftaroline Ceftazidime/avibactam Ceftolozane/tazobactam Chloramphenicol (The oral formulation is no longer made in the U.S.) Cidofovir Daptomycin Fidaxomicin PO Flucytosine PO Foscarnet Fosfomycin PO IG Need ID approval/consult for any infectious diseases indications (i.e. C. difficile colitis, group A streptococcal or MRSA toxic shock syndrome). Meropenem Micafungin ID consultation/approval is not required for 50 mg daily doses in allogeneic stem cell recipients who require antifungal prophylaxis. Pentamidine Polymyxin B Pyrimethamine PO Ribavirin Inhalation Tigecycline Voriconazole, PO Category II - I.D. stewardship approval must be requested from 9:30 a.m. 5:00 p.m. From 5:01 p.m. 9:29 a.m. M-F, on weekends, or holidays, pharmacy will authorize a sufficient duration of therapy until the next antimicrobial stewardship business day. ID consultation may be suggested, but is not required. Oseltamivir Oral Category III A - I.D. stewardship approval must be requested from 9:30 am to 5:00 pm From 5:01 p.m. 9:29 a.m. M-F, on weekends, or holidays, pharmacy will authorize a sufficient duration of therapy until the next antimicrobial stewardship business day. ID consultation may be suggested, but is not required. Acyclovir Approval is not required for 250 mg q12h prophylaxis doses in stem cell recipients unable to take oral valacyclovir. Albendazole PO Amikacin, IM Azithromycin Approval not required for 1 st dose ordered via Severe Sepsis Protocol Aztreonam Approval not required for 1 st dose ordered via Severe Sepsis Protocol Cefotaxime For Pediatrics only (ceftriaxone should be used for adults) Ceftriaxone Approval is not required for doses up to 1000 mg per day. 1 st dose of > 1 gm is exempt from approval if ordered via Severe Sepsis Protocol. Ciprofloxacin Approval is not required for prophylaxis doses in stem cell transplant recipients or for 1 st dose ordered via Severe Sepsis Protocol. Patients are automatically switched to the oral formulation when able to take oral medications. Clarithromycin PO Approval is not required for the treatment of Mycobacterium avium and H. pylori infections. Fluconazole, PO Approval is not required for H patients and for prophylaxis in stem cell recipients receiving up to 400 mg per day. Approval is not required for prophylaxis doses in stem cell recipients, for single 150 mg oral doses for candidal vaginitis, or in neonates using doses of 3 mg/kg Q 72 hours; patients are automatically switched to the oral formulation when able to take oral medications Ganciclovir Itraconazole PO Ivermectin PO Levofloxacin, PO Approval is not required for oral doses 500 mg daily. Patients are automatically switched to the oral formulation when able to take oral medications Penicillin G benzathine (Bicillin LA) IM Posaconazole PO (Please note suspension and extended-release tablet dosing is NOT interchangeable) Tobramycin Inhalation Vancomycin PO, rectal Category III B - I.D. approval required to continue past the initial 72 hours of therapy. From 5:01 p.m. 9:29 a.m. M-F, on weekends, or holidays, pharmacy will authorize a sufficient duration of therapy until the next antimicrobial stewardship business day. ID consultation is suggested, but not required. Cefepime Approval not required for 1 st dose ordered via Severe Sepsis Protocol Piperacillin/tazobactam Approval not required for 1 st dose ordered via Severe Sepsis Protocol Vancomycin *Antimicrobial Stewardship reserves the right to restrict antimicrobials whose supply is critically short (i.e. nationwide drug shortage)* **Approvals for patients 21 years of age should be directed to the adult stewardship pager, while approvals for patients < 21 years of age should be directed to the pediatric stewardship pager** 5

6 Table 5. Restricted Antimicrobial List for (CHAM Pediatrics) As Of January 2017 Acyclovir, Oral One dose exceptions are the emergency room for fever in baby < 8 weeks, severe sepsis and possible meningitis Albendazole Oral Amantadine Oral Amikacin, IM One dose exception for severe sepsis Ampho b dexoycholate Ampho b lipid complex Aztreonam One dose exception for severe sepsis. Cefepime Approvals are exempt on CHAM 9 and CHAM 10. One dose exceptions are for severe sepsis, possible meningitis, and febrile neutropenia (in ER only) Ceftaroline Chloramphenicol The oral formulation is no longer made in the U.S., and is unavailable. Cidofovir Ciprofloxacin Oral, One dose exception for severe sepsis Clarithromycin Oral Colistin Nebulizer Inhalation Daptomycin Fluconazole Oral, Flucytosine Oral Foscarnet Ganciclovir Itraconazole Oral Levofloxacin Oral, One dose exception for severe sepsis Linezolid Oral, One dose exception for severe sepsis Meropenem One dose exception for severe sepsis Micafungin Oseltamivir Oral For treatment, answer choices in the EPIC ordering set are mandatory Palivizumab IM,, must be evaluated by an ASP member from 8 a.m. 5 p.m. Monday through Friday Pentamidine, Inhalation Polymyxin B Ribavirin Oral, Inhalation Posaconazole Oral, Rimantidine Oral Tigecycline Tobramycin, IM, Inhalation Valganciclovir PO Vancomycin, oral, rectal One dose exceptions are for severe sepsis and possible meningitis Voriconazole Oral, 6

7 Table 6. Restricted Antimicrobial List for (Einstein and Wakefield NICU) as of January 2017 Acyclovir One dose exception for severe sepsis Albendazole Oral Amantadine Oral Amikacin and IM One dose exception for severe sepsis Ampho b deoxycholate Ampho b lipid complex Aztreonam Cefepime Chloramphenicol The oral formulation is no longer made in the U.S., and is unavailable. Cidofovir Ciprofloxacin One dose exception for severe sepsis Clarithromycin Oral Daptomycin Fluconazole and oral Approval is not required in neonates using doses of 3mg/kg q72h. Flucytosine Oral Foscarnet Ganciclovir Itraconazole Oral Imipenem Levofloxacin One dose exception for severe sepsis Linezolid and oral One dose exception for severe sepsis Meropenem One dose exception for severe sepsis Micafungin Oseltamivir Oral For treatment, answer choices in the EPIC ordering set are mandatory Pentamidine Polymyxin B Ribavirin Oral, Inhalation Rimantadine Oral Tigecycline Tobramycin Inhalation Approval is not required for the and IM formulations. Valganciclovir PO Vancomycin, One dose exception for severe sepsis Vancomycin PO and Rectal Voriconazole and oral 7

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.

More information

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016 Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology

More information

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal

More information

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.

More information

Mortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project

Mortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project Libby, MT Sepsis Quality Improvement Project Barb Dumont RN, Director of Quality and Risk Management Mike Julius RN, ED Manager Cathy Wolfe RN, Chief Nursing Officer. Mortality Rate was unsightly!!! percent

More information

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017)

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Introduction The dosing recommendations presented here are for adults with moderate-to-severe infections and are

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin

More information

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,

More information

Antimicrobial Stewardship: A System- Wide Approach at Carolinas HealthCare System

Antimicrobial Stewardship: A System- Wide Approach at Carolinas HealthCare System Antimicrobial Stewardship: A System- Wide Approach at Carolinas HealthCare System Kelly Goodson, PharmD; Erin Roach, Pharmd; Susan Bear, PharmD; Lisa Davidson, MD Carolinas HealthCare System is one of

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides

More information

PPP 1. Continuation, modification, and discontinuation of a medication

PPP 1. Continuation, modification, and discontinuation of a medication PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...

More information

Neutropenic Fever 1 InpatientPediatric Treatment

Neutropenic Fever 1 InpatientPediatric Treatment Neutropenic Fever InpatientPediatric Treatment (Hematologic Cancers and Stem Cell Patients) te: This algorithm should not be used for patients receiving CAR cell therapy. Page of 8 Patient presents with

More information

Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department

Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010

More information

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE GUIDELINES FOR USERS 17th Edition 2011 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology North

More information

Chapter 5 ~ Infections

Chapter 5 ~ Infections Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy

More information

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin

More information

Antibiotic Dosing in the Elderly

Antibiotic Dosing in the Elderly Antibiotic Dosing in the Elderly Philip Chung, PharmD, MS, BCPS Nebraska ASAP Community Network Pharmacy Coordinator Nebraska Medicine Disclosure I have no relevant disclosure The presentation includes

More information

Neutropenic Fever 1 InpatientPediatric Treatment

Neutropenic Fever 1 InpatientPediatric Treatment Neutropenic Fever 1 InpatientPediatric Treatment (Solid Tumors) Note: This algorithm should not be used for patients receiving CAR cell therapy. Page 1 of 7 Patient presents with fever or develops fever

More information

Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines

Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines Inclusion Criteria: Age 1 year with cystic fibrosis admitted for a pulmonary exacerbation. Exclusion Criteria: ICU Admission Newborn with

More information

Antimicrobial Management of Febrile Neutropenic Sepsis

Antimicrobial Management of Febrile Neutropenic Sepsis Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:

More information

Ready to answer the questions?

Ready to answer the questions? 파워포인트문서의제목 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America.

More information

Condition Major Pathogens First Choice Therapy Alternative Therapy Comments. Clinically stable: Clindamycin 13mg/kg/dose IV q8h (max 900mg/dose)

Condition Major Pathogens First Choice Therapy Alternative Therapy Comments. Clinically stable: Clindamycin 13mg/kg/dose IV q8h (max 900mg/dose) BONE JOINT INFECTIONS... 1 CNS INFECTIONS... 2 GASTROINTESTINAL INFECTIONS... 3 FEVER IN ONCOLOGY BMT PATIENTS... 4 FEVER WITHOUT A SOURCE, YOUNG INFANT... 5 HEAD NECK INFECTIONS... 6 INTRA-ABDOMINAL INFECTIONS...

More information

UPDATE ON FEBRILE NEUTROPENIA

UPDATE ON FEBRILE NEUTROPENIA UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer

More information

Neutropenic Fever. CID 2011; 52 (4):e56-e93

Neutropenic Fever.  CID 2011; 52 (4):e56-e93 Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

Neutropenic Sepsis Guideline

Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt

More information

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views

More information

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007)

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007) 1 Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists

More information

Outline of presentation. Pinyo Rattanaumpawan; Sajja Supornpun; Basic Concepts of ASP Research to Practice in ASP ASP Siriraj

Outline of presentation. Pinyo Rattanaumpawan; Sajja Supornpun; Basic Concepts of ASP Research to Practice in ASP ASP Siriraj 1 Pinyo Rattanaumpawan; MD, MSCE, PhD Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Sajja Supornpun; BPharm, MS Department of Pharmacy,

More information

104 MMWR December 17, 2004

104 MMWR December 17, 2004 104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir

More information

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist

EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? 1.-CRRT : A «Lego» Module? 4.-Antibiotic Adaptation During Low Dose CRRT? 2.- CRRT + ECMO: What to do? 5.-

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment

Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus

More information

Form 2046 R3.0: Fungal Infection Pre-HSCT Date

Form 2046 R3.0: Fungal Infection Pre-HSCT Date Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

Non-Beta-lactam Antibiotic: Testing and Desensitization

Non-Beta-lactam Antibiotic: Testing and Desensitization Non-Beta-lactam Antibiotic: Testing and Desensitization David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology 1 Disclosures n Research Grants n

More information

Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update

Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update Prevention and Treatment of Selected Opportunistic Infections: A Guidelines Update Constance A. Benson, MD Professor of Medicine Division of Infectious Diseases University of California, San Diego Disclosures

More information

Inpatient Beta-lactam Allergy Guideline

Inpatient Beta-lactam Allergy Guideline I. PURPOSE To guide clinicians in prescribing antibiotics for pediatric and adult inpatients with known or suspected history of allergic reactions to beta-lactam antibiotics. Inclusion/Exclusion This guideline

More information

EAU GUIDELINES ON UROLOGICAL INFECTIONS

EAU GUIDELINES ON UROLOGICAL INFECTIONS EAU GUIDELINES ON UROLOGICAL INFECTIONS (Limited text update March 2018) G. Bonkat (Co-chair), R. Pickard (Co-chair), R. Bartoletti, T. Cai, F. Bruyere, S.E. Geerlings, B. Köves, F. Wagenlehner Guidelines

More information

Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section

Report generated from BNF provided by FormularyComplete (  Accessed TA Number. Title Formulary Status Section Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACICLOVIR Aciclovir 5.3 Antiviral drugs->5.3.2

More information

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of

More information

Guidelines in the Management of Febrile Neutropenia for Clinical Practice

Guidelines in the Management of Febrile Neutropenia for Clinical Practice REFERENCES 1. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477-3484.

More information

Antifungal Treatment in Neonates

Antifungal Treatment in Neonates Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1

More information

This letter authorises the extended use of the following guidance until 1st December 2018:

This letter authorises the extended use of the following guidance until 1st December 2018: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224

More information

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS THERAPY USING ANTIFUNGALS AND ANTIVIRALS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu CLASSIFICATION OF FUNGI Yeasts Candida Cryptococcus

More information

Learning Objectives. Introduction. Types of IV to PO Therapy Conversions. Chapter 29 Intravenous to Oral Therapy Conversion. Kristi M.

Learning Objectives. Introduction. Types of IV to PO Therapy Conversions. Chapter 29 Intravenous to Oral Therapy Conversion. Kristi M. Chapter 29 Intravenous to Oral Therapy Conversion Learning Objectives Kristi M. Kuper 1. Explain the rationale behind an intravenous (IV) to oral (PO) therapy conversion program. 2. Differentiate between

More information

Evelina London Children s Hospital (ELCH)

Evelina London Children s Hospital (ELCH) Evelina London Children s Hospital (ELCH) Lead Consultant Jenny Handforth PID Pharmacist Faye Chappell Paediatric OPAT CNS Vacant Overview Paediatric OPAT in London Paediatric OPAT ELCH Children s Hospital

More information

Table 1. Prophylaxis to Prevent First Episode of Opportunistic Disease (page 1 of 5) (Last updated May 7, 2013; last reviewed May 7, 2013)

Table 1. Prophylaxis to Prevent First Episode of Opportunistic Disease (page 1 of 5) (Last updated May 7, 2013; last reviewed May 7, 2013) Table 1. Prophylaxis to Prevent First Episode of Disease (page 1 of 5) (Last updated May 7, 2013; last reviewed May 7, 2013) s Indication Preferred Alternative Pneumocystis pneumonia (PCP) CD4 count

More information

Stanford Health Care Last Review Date: 8/2016 Pharmacy Department Policies and Procedures

Stanford Health Care Last Review Date: 8/2016 Pharmacy Department Policies and Procedures Medication Administration: Extended-Infusion Piperacillin/Tazobactam (Zosyn ) Protocol Related Documents: Patient Care Manual Guide: Medication Administration IV Infusion Guidelines I. PURPOSE Dose optimization

More information

Challenges of therapeutic drug monitoring in paediatrics

Challenges of therapeutic drug monitoring in paediatrics Challenges of therapeutic drug monitoring in paediatrics Jim Gray Consultant Microbiologist Birmingham Children s Hospital, UK Overview Outline of the challenges Efficient TDM TDM in children: why and

More information

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification

More information

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,

More information

An Update in the Management of Candidiasis

An Update in the Management of Candidiasis An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College

More information

Objectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children

Objectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,

More information

Condition First line Alternative Comments Candidemia Nonneutropenic adults

Condition First line Alternative Comments Candidemia Nonneutropenic adults Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative

More information

TREATMENT AND PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS IN HIV (Except Mycobacterium tuberculosis)

TREATMENT AND PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS IN HIV (Except Mycobacterium tuberculosis) TREATMENT AND PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS IN HIV (Except Mycobacterium tuberculosis) All doses stated should be reviewed f each individual patient and adjusted if they have renal liver impairment.

More information

PHYSICIAN S ORDERS Page 1 of 5 PNEUMONIA. Resuscitation (Code)Status: Admit to: Diagnosis: Pneumonia Other: Consult:

PHYSICIAN S ORDERS Page 1 of 5 PNEUMONIA. Resuscitation (Code)Status: Admit to: Diagnosis: Pneumonia Other: Consult: Inpatient Observation Bed Type: Med/Surg PHYSICIAN S ORDERS Page 1 of 5 Satellite Telemetry Telemetry ICU Resuscitation (Code)Status: Admit to: Diagnosis: Pneumonia Other: Consult: Condition: Stable Guarded

More information

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer

Journey to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical

More information

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Infections therapeutic group PTAC and Subcommittee of PTAC minutes are

More information

Clinical Pearls Infectious Diseases. Pritish K. Tosh, MD MN ACP Nov 7, [Answers and discussion slides will be posted after the meeting]

Clinical Pearls Infectious Diseases. Pritish K. Tosh, MD MN ACP Nov 7, [Answers and discussion slides will be posted after the meeting] Clinical Pearls Infectious Diseases Pritish K. Tosh, MD MN ACP Nov 7, 2014 [Answers and discussion slides will be posted after the meeting] Case 1 A 33-year-old male with diffuse large B-cell lymphoma

More information

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:

More information

No Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs

No Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs ASCENSION TEXAS No Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs Austin Area Society of Health-System Pharmacists April 26, 2018 Amy Carr, PharmD PGY-2 Infectious Diseases Pharmacy

More information

Penicillin Allergy Guidance Document

Penicillin Allergy Guidance Document Key Points Penicillin Allergy Guidance Document Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin

More information

Guidebook for ED and Inpatient Sepsis Order Set Initiatives 2018

Guidebook for ED and Inpatient Sepsis Order Set Initiatives 2018 Background The leadership of the Surviving Sepsis Campaign (SSC) believes, since its inception, that both the SSC Guidelines and the SSC performance improvement indicators (1) will evolve as new evidence

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES

NEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES Lisa G. Winston, MD Professor, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital Epidemiologist, San Francisco General Hospital NEW DEVELOPMENTS AND CHALLENGING

More information

LRI Children s Hospital

LRI Children s Hospital Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval

More information

life-threatening infections

life-threatening infections Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal

More information

Acetylcysteine Inhalation Solution

Acetylcysteine Inhalation Solution Drug Shortage information Action Plan delays and another manufacturer voluntarily suspending production. Hospira has a limited supply available and other manufacturers unable to estimate a release date.

More information

Novel Use of Antibiotics and the Role of Pharmacy Technicians in Improving Outcomes

Novel Use of Antibiotics and the Role of Pharmacy Technicians in Improving Outcomes Technician Education Day April 26, 2014 Bradenton, FL Novel Use of Antibiotics and the Role of Pharmacy Technicians in Improving Outcomes Jamie Kisgen, Pharm.D., BCPS Pharmacotherapy Specialist Infectious

More information

Antifungals and current treatment guidelines in pediatrics and neonatology

Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org

More information

2019 PHP PRIMARY CARE INCENTIVE

2019 PHP PRIMARY CARE INCENTIVE Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described

More information

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg. AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Prevymis) Reference Number: CP.PHAR.367 Effective Date: 11.28.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

Copyright 2012 Oregon State University. All Rights Reserved

Copyright 2012 Oregon State University. All Rights Reserved Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Infected cardiac-implantable electronic devices: diagnosis, and treatment

Infected cardiac-implantable electronic devices: diagnosis, and treatment Infected cardiac-implantable electronic devices: diagnosis, and treatment The incidence of infection following implantation of cardiac implantable electronic devices (CIEDs) is increasing at a faster rate

More information

Red Book : 2006 Report of the Committee on Infectious Diseases. Errata (4/11/07)

Red Book : 2006 Report of the Committee on Infectious Diseases. Errata (4/11/07) Red Book : 2006 Report of the Committee on Infectious Diseases Errata (4/11/07) For the most up-to-date list of important Red Book errata, please visit the Red Book Online Web site at http://www.aapredbook.org.

More information

Physician's Core Measure Pocket Guide AMI

Physician's Core Measure Pocket Guide AMI Physician's Core Measure Pocket Guide Core Measure Hotline: Ext. 4448 http://centegramedsource.com Indicator: AMI AMI VER. 9/2018 MUST document WHY no ASA unless there is documentation of contraindication

More information

Beta lactam Allergies Facts vs. Fears

Beta lactam Allergies Facts vs. Fears 1 Beta lactam Allergies Facts vs. Fears Meghan Jeffres, PharmD Assistant Professor, Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy Statement of Disclosures 2 No financial

More information

Alaris System Profile Report RELEASED. Stepdown. VUMC - 3/18/ :20 Page 1 of 19 VUMC O, 018d997b6-R

Alaris System Profile Report RELEASED. Stepdown. VUMC - 3/18/ :20 Page 1 of 19 VUMC O, 018d997b6-R Alaris System Profile Report RELEASED Stepdown VUMC - 3/18/2013 09:20 Page 1 of 19 1. Current Data Set Status Data Set Name Hospital Name Data Set ID Data Set Status VUMC 9.4 2013 O VUMC 018d997b6-R Released

More information

Synthroid oral to iv conversion

Synthroid oral to iv conversion Synthroid oral to iv conversion The Borg System is 100 % Synthroid oral to iv conversion Synthroid official prescribing information for healthcare professionals. Includes: indications, dosage, adverse

More information

MICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS

MICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing

More information

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).

More information

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence

Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs

More information

Septic shock. Babak Tamizi Far M.D Isfahan university of medical sciences

Septic shock. Babak Tamizi Far M.D Isfahan university of medical sciences Septic shock Babak Tamizi Far M.D Isfahan university of medical sciences Definitions Used to Describe the Condition of Septic Patients Approximately 750,000 cases of severe sepsis or septic shock occur

More information

Alabama Medicaid Pharmacist

Alabama Medicaid Pharmacist Alabama Medicaid Pharmacist Published Quarterly by Health Information Designs, LLC, Winter 015 edition A Service of Alabama Medicaid PDL Update Effective January 5, 015, the Alabama Medicaid Agency will

More information

The Epidemiology of Candidaemia in Northern Ireland

The Epidemiology of Candidaemia in Northern Ireland The Epidemiology of Candidaemia in Northern Ireland 2001-2011 November 2013 1 Executive Summary In Northern Ireland (NI), over the last decade, the analysis of trends from voluntarily reported laboratory

More information

Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008

Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes

More information

Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital

Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Respiratory tract infections in children Uncomplicated URTI A child with a cold should not receive an antibiotic Paracetamol (15 mg/kg/dose

More information

IV 5 mg/kg q12h 5 mg/kg q24h 2.5 mg/kg q24h mg/kg q24h (post HD) 50% standard dose q24h 5 mg/kg q24h. IV 5-10 mg/kg q12h

IV 5 mg/kg q12h 5 mg/kg q24h 2.5 mg/kg q24h mg/kg q24h (post HD) 50% standard dose q24h 5 mg/kg q24h. IV 5-10 mg/kg q12h Page 1 of 18 male: = (140-Age) IBW Drug Name Usual Dose (Normal Renal Function) CrCl (ml/min) Dose Adjustment (In renal insufficiency) Acyclovir (Zovirax) *Use IBW Mucosal & cutaneous IV: 5 mg/kg q8h PO:

More information

Antibiotic guideline in Adult Cystic Fibrosis

Antibiotic guideline in Adult Cystic Fibrosis Adapted f Use in NHS Tayside January 2015 Antibiotic guideline in Adult Cystic Fibrosis Choice of antibiotics in cystic fibrosis is based on several facts including ganism sensitivity, histy of adverse

More information

PK/PD degli antibiotici utilizzati nella sepsi

PK/PD degli antibiotici utilizzati nella sepsi PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill

More information

Acute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016

Acute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016 Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis

More information

High risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR

High risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Prevymis) Reference Number: CP.PHAR.367 Effective Date: 11.28.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing

Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing October 11, 2017 Paul Lewis, PharmD, BCPS (AQ-ID) Johnson City Medical Center Johnson City, TN 1 Outline Introduction to stewardship

More information

Other β-lactam. A. Carbapenems:

Other β-lactam. A. Carbapenems: A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,

More information